Correlation Between Viatris and Esperion Therapeutics

Can any of the company-specific risk be diversified away by investing in both Viatris and Esperion Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viatris and Esperion Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viatris and Esperion Therapeutics, you can compare the effects of market volatilities on Viatris and Esperion Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viatris with a short position of Esperion Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viatris and Esperion Therapeutics.

Diversification Opportunities for Viatris and Esperion Therapeutics

0.88

Correlation Coefficient

Viatris  Esperion Therapeutics

Very poor diversification

The 3 months correlation between Viatris and Esperion is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Viatris and Esperion Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Esperion Therapeutics and Viatris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viatris are associated (or correlated) with Esperion Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Esperion Therapeutics has no effect on the direction of Viatris i.e., Viatris and Esperion Therapeutics go up and down completely randomly.

Pair Corralation between Viatris and Esperion Therapeutics

Given the investment horizon of 90 days Viatris is expected to under-perform the Esperion Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Viatris is 1.51 times less risky than Esperion Therapeutics. The stock trades about -0.22 of its potential returns per unit of risk. The Esperion Therapeutics is currently generating about -0.14 of returns per unit of risk over similar time horizon. If you would invest  215.00  in Esperion Therapeutics on December 30, 2024 and sell it today you would lose (65.00) from holding Esperion Therapeutics or give up 30.23% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Viatris  vs.  Esperion Therapeutics

Viatris

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viatris has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Viatris and Esperion Therapeutics

The main advantage of trading using opposite Viatris and Esperion Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viatris position performs unexpectedly, Esperion Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will offset losses from the drop in Esperion Therapeutics' long position.

The idea behind Viatris and Esperion Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.